Novavax Inc. ($NVAX) Stock Forecast: Down 5.1% Today

What is Novavax Inc.?

Novavax (NVAX) is a biotechnology company focused on developing vaccines for infectious diseases. The overall market sentiment for the company has been bearish today.

Why is Novavax Inc. going down?

NVAX stock is down 5.1% on Feb 19, 2025 16:48

• The bearish movement in NVAX's stock could be due to investors' concerns about the updates on its pipeline during the fourth-quarter earnings call.
• If the updates on the pipeline did not meet investors' expectations, it could have led to a sell-off of NVAX shares.
• The market might be reacting negatively to any delays or setbacks in the development of Novavax's vaccines, leading to a decline in the stock price.

NVAX Price Chart

NVAX Technical Analysis

NVAX News

Novavax to Report Q4 Earnings: Here's What You Can Expect

On NVAX's fourth-quarter earnings call, investors will likely focus on updates on its pipeline.

https://www.zacks.com/stock/news/2417885/novavax-to-report-q4-earnings-heres-what-you-can-expect

Trending Today

Maker ($MKR) Crypto Forecast: Up 5.1% Today

Sonic (prev. FTM) ($S) Crypto Forecast: Up 5.1% Today

Golem ($GLM) Crypto Forecast: Up 31.6% Today

Optimism ($OP) Crypto Forecast: Up 5.6% Today

MANTRA ($OM) Crypto Forecast: Up 10.9% Today

NEAR Protocol ($NEAR) Crypto Forecast: Down 5.1% Today

Memecoin ($MEME) Crypto Forecast: Up 5.7% Today

Ethereum ($ETH) Crypto Forecast: Up 5.1% Today

Pepe ($PEPE) Crypto Forecast: Up 5.0% Today

Ethena ($ENA) Crypto Forecast: Down 6.0% Today

Novavax Inc. Price History

07.00.2025 - NVAX Stock was up 12.2%

• NVAX stock experienced a strong bullish movement following reports of the first human death in the U.S. related to the H5N1 bird flu virus and high levels of respiratory illnesses nationwide.
• The sharp increase in respiratory illnesses highlighted in a recent CDC report has led to increased investor interest in Novavax's vaccine development efforts.
• The market movement reflects the growing demand for vaccines and medical solutions in response to public health concerns, driving up NVAX stock prices significantly.

23.00.2025 - NVAX Stock was down 5.1%

• Wall Street analysts hold an optimistic view on the stock, projecting an 81.6% upside potential. However, NVAX faced significant bearish activity today.
• The discrepancy between the upbeat price targets and the current market performance may stem from profit-taking by investors capitalizing on past gains.
• Concerns about the company meeting analysts' high expectations could be prompting investors to sell their shares.
• Market dynamics, including broader economic conditions and sector rotation, may also be influencing the movement of NVAX and other high-growth stocks.

07.00.2025 - NVAX Stock was up 15.2%

• NVAX stock increased by 13.5%.
• The rise in respiratory illnesses in the United States possibly boosted investor confidence in Novavax's vaccine development.
• Positive updates on the effectiveness of Novavax's vaccines in treating respiratory illnesses influenced the bullish movement in NVAX stock.

06.11.2024 - NVAX Stock was up 10.0%

• Novavax (NVAX) saw a significant increase in its stock price after announcing the sale of its Czech manufacturing facility to Novo Nordisk for $200 million.
• The sale is anticipated to provide Novavax with additional funds to enhance its vaccine pipeline, likely boosting investor confidence in the company's future prospects.
• This strategic decision not only infuses capital into Novavax but also enables them to streamline operations and concentrate on their core expertise of vaccine development, potentially resulting in sustained growth and advancements in the industry.

12.11.2024 - NVAX Stock was up 5.1%

• NVAX stock surged as the company announced the start of a late-stage study on COVID-19-flu combination and standalone flu vaccines, indicating progress in its vaccine development efforts.
• The FDA granting Fast Track designation to Sanofi's vaccine candidates for COVID-19 and influenza may have positively impacted NVAX, as it highlights the importance and potential demand for such vaccines.
• Despite some negative sentiment from Jim Cramer, the news of Novavax selling its manufacturing plant for $200 million to Novo Nordisk could be seen as a strategic move to streamline operations and focus on vaccine development, which investors may have viewed favorably.
• Overall, the bullish movement in NVAX could be attributed to positive developments in its vaccine pipeline and strategic decisions to strengthen its position in the market.

14.01.2025 - NVAX Stock was up 6.4%

• Novavax (NVAX) exhibited strong bullish movement today, outperforming the broader market.
• The stock concluded the trading day at $8.19, reflecting a +0.74% change compared to the previous session.
• Factors contributing to this bullish trend could include advancements in Novavax's vaccine research or general market optimism towards the healthcare sector.
• Investors are displaying faith in Novavax's capacity to combat infectious diseases, propelling the stock's upward trajectory.

19.01.2025 - NVAX Stock was down 5.1%

• The bearish movement in NVAX's stock could be due to investors' concerns about the updates on its pipeline during the fourth-quarter earnings call.
• If the updates on the pipeline did not meet investors' expectations, it could have led to a sell-off of NVAX shares.
• The market might be reacting negatively to any delays or setbacks in the development of Novavax's vaccines, leading to a decline in the stock price.

08.00.2025 - NVAX Stock was down 9.3%

• The dip in NVAX stock today may be due to investors taking profits after a recent rise in share price.
• Despite optimistic reports on Novavax's vaccine development and recent share price increase, the absence of significant improvements in earnings estimate revisions may have prompted some investors to sell their holdings.
• The surge in vaccine stocks, including Novavax, in response to news of the first human death in the U.S. from the H5N1 bird flu virus and increased incidents of respiratory illnesses nationwide likely initially bolstered NVAX but could have led to profit-taking today.

05.01.2025 - NVAX Stock was up 5.0%

• Novavax (NVAX) had a bullish trajectory, surpassing the overall market performance.
• The upturn in stock value may be linked to favorable developments within the company, possibly connected to progress in vaccine research and clinical trials.
• Investors are exhibiting confidence in Novavax's ability to tackle global health issues, leading to increased investment and pushing up the stock price.
• The market's reaction indicates optimism about Novavax's future outlook and its efforts in combatting infectious diseases.

15.00.2025 - NVAX Stock was up 5.1%

• NVAX demonstrated strong bullish momentum today amidst recent stock volatility.
• A bearish market trend earlier in the week was impacted by adverse news in the vaccine industry, including Moderna's revenue guidance being below expectations and respiratory illness concerns.
• Despite challenges within the vaccine sector, NVAX surged today, potentially driven by positive advancements in its vaccine pipeline or a shift in market sentiment in its favor.
• Investors might be reconsidering NVAX's long-term prospects, leading to the bullish movement in spite of recent industry setbacks.

09.00.2025 - NVAX Stock was down 11.2%

• Novavax (NVAX) witnessed a significant 11.2% decrease in its shares amid a strong bearish movement today.
• Investor sentiment turned negative due to reports of the first human death in the U.S. linked to the H5N1 bird flu virus and information from a major health organization about the rise in respiratory illnesses. This caused volatility in the vaccine stock sector.
• While there was a noteworthy 13.5% surge in the share price recently following reports of a sharp uptick in respiratory illnesses by the aforementioned health organization, apprehensions stemming from the bird flu fatality dampened overall investor confidence, leading to the bearish sentiment.
• The conflicting information and uncertainties surrounding respiratory illnesses, as well as the progress in vaccine development, likely contributed to the stock's erratic performance and subsequent decline.

16.00.2025 - NVAX Stock was down 5.1%

• Novavax (NVAX) witnessed a significant drop of 9.8% in its stock price today.
• The decrease in Novavax's stock value is linked to the pessimistic outlook surrounding vaccine stocks, influenced by Moderna's lower 2025 revenue projections.
• Moreover, the fluctuating nature of vaccine stocks, triggered by recent occurrences like the first US bird flu fatality and a report from the CDC highlighting an increase in respiratory illnesses, likely played a role in today's downturn for Novavax.